Expression of the tight junction protein Zonula-occludens-1 (ZO-1) in primary human retinal pigment epithelial cells. Credit: Matthew Campbell/Arvydas Maminishkis
Scientists at Trinity College Dublin have made a major breakthrough with important implications for sufferers of the eye disease Age-Related Macular Degeneration (AMD), which can cause central blindness in sufferers.
The scientists found that a component of the immune system, 'IL-18', acts as a guardian of eyesight by suppressing the production of damaging blood vessels behind the retina at the back of the eye. In addition, in pre-clinical models, it was shown that 'IL-18' can be administered in a non-invasive way, which could represent a major improvement on the current therapeutic options that are open to patients.
"We were initially concerned that IL-18 might cause damage to the sensitive cells of the retina, because it is typically linked to inflammation. But surprisingly we found that low doses had no adverse effects on the retina and yet still suppressed abnormal blood vessel growth," said Assistant Professor in Immunology at Trinity, Sarah Doyle, who is the first author on the paper.
AMD is one of the most common forms of blindness in the aging population. The disease involves a loss of central vision, such that people suffering at advanced stages are unable to read, watch TV, drive, or use computers.
This video is not supported by your browser at this time.
There are two forms of AMD: 'dry' and 'wet'. Dry AMD accounts for the majority of cases, but wet AMD causes over 90% of blindness associated with the disease. In wet AMD, blood vessels underneath the retina begin to grow abnormally, which causes almost immediate central blindness. Because central vision accounts for almost all of our daytime visual acuity, wet AMD sufferers experience severe and profound day-to-day challenges.
Treatment options for wet AMD are currently limited to the end stages of the disease. Regular injections of antibodies must be made directly into the eye to mop up a problematic molecule termed 'VEGF'. However, the Trinity scientists found that IL-18 directly inhibits VEGF production, and that it can work as effectively as the current treatment when administered via a non-invasive intravenous injection in pre-clinical settings.
"Our findings have highlighted the power of industry-academic collaborations, the results of which should lead to clinical deployment of IL-18 as a treatment for AMD in the short term," added Research Assistant Professor in Genetics at Trinity, Matthew Campbell.
The research, published online this week in the high-profile international journal, Science Translational Medicine, was supported by Enterprise Ireland (EI), Science Foundation Ireland (SFI), the US-based charity Brightfocus Foundation, and major pharmaceutical company GlaxoSmithKline (GSK).
Vice President of Ophthalmology at GSK, Dr Pete Adamson, said: "A greater understanding of the molecular complexity of diseases such as AMD is critical to the development of new medicines."
Explore further: Impaired autophagy associated with age-related macular degeneration
More information: "IL-18 Attenuates Experimental Choroidal Nascularization as a Potential Therapy for Wet Age-Related Macular Degeneration," by S.L. Doyle et al. Science Translational Medicine, 2014.
Medical Xpress on facebook
Related Stories
Scientists report major breakthrough in age-related macular degeneration prevention
Apr 08, 2012
Scientists at Trinity College Dublin have discovered that a part of the immune system called the inflammasome is involved in regulating the development of one of the most common forms of blindness, called Age-Related Macular ...
Impaired autophagy associated with age-related macular degeneration
Aug 21, 2013
A new study published in the prestigious PLoS One journal changes our understanding of the pathogenesis of age-related macular degeneration (AMD). The researchers found that degenerative changes and loss of vision are ca ...
Age-related macular degeneration treatment works even with other eye problem
Nov 11, 2012
The primary treatment for wet macular degeneration, a chronic eye condition that causes vision loss, is effective even if patients have macular traction problems, a Mayo Clinic study shows. The findings will be presented ...
Team finds potential topical treatment for macular degeneration
Oct 09, 2013
Researchers from Tufts University School of Medicine and the Sackler School of Graduate Biomedical Sciences have identified a possible topical treatment for age-related macular degeneration (AMD) in a study of mice that shows ...
Nano innovation could mean eye injections are a thing of the past
Mar 05, 2014
Drugs used to treat blindness-causing disorders could be successfully administered by eye drops rather than unpleasant and expensive eye injections, according to new research led by UCL scientists that could be a breakthrough ...
Recommended for you
New non-surgical treatment for common, vexing eye condition
Mar 31, 2014
A new report reveals a potential breakthrough in the treatment of a common eye ailment known as pterygium (Surfer's eye) that impacts the vision, eye health, and cosmetic appearance of countless sufferers.
Rates of blindness and partial sight have plummeted in developed world
Mar 24, 2014
Rates of blindness and impaired eyesight have plummeted over the past 20 years in the developed world. But macular degeneration has replaced cataract as the leading cause of blindness in rich countries, reveals an analysis ...
Physical activity and occasional drinking found to be associated with decrease in vision impairment
Mar 19, 2014
A physically active lifestyle and occasional drinking is associated with a reduced risk of developing visual impairment, according to a study published online this month in Ophthalmology, the journal of the American Academ ...
Color vision tends to fade with age, study finds
Mar 18, 2014
(HealthDay)—Here's one more ability that seems to decline with age: color sense. A new study finds that many people lose their ability to clearly distinguish certain colors as they age, with losses typically ...
Drivers with hemianopia fail to detect pedestrians
Mar 14, 2014
A diagnosis of hemianopia, or blindness in one half of the visual field in both eyes as the result of strokes, tumors or trauma often means the end of driving.
Smartphones become 'eye-phones' with low-cost devices developed by Stanford
Mar 07, 2014
Researchers at the Stanford University School of Medicine have developed two inexpensive adapters that enable a smartphone to capture high-quality images of the front and back of the eye. The adapters make ...
User comments
© Medical Xpress 2011-2014, Science X network
Expression of the tight junction protein Zonula-occludens-1 (ZO-1) in primary human retinal pigment epithelial cells. Credit: Matthew Campbell/Arvydas Maminishkis
Scientists at Trinity College Dublin have made a major breakthrough with important implications for sufferers of the eye disease Age-Related Macular Degeneration (AMD), which can cause central blindness in sufferers.
The scientists found that a component of the immune system, 'IL-18', acts as a guardian of eyesight by suppressing the production of damaging blood vessels behind the retina at the back of the eye. In addition, in pre-clinical models, it was shown that 'IL-18' can be administered in a non-invasive way, which could represent a major improvement on the current therapeutic options that are open to patients.
"We were initially concerned that IL-18 might cause damage to the sensitive cells of the retina, because it is typically linked to inflammation. But surprisingly we found that low doses had no adverse effects on the retina and yet still suppressed abnormal blood vessel growth," said Assistant Professor in Immunology at Trinity, Sarah Doyle, who is the first author on the paper.
AMD is one of the most common forms of blindness in the aging population. The disease involves a loss of central vision, such that people suffering at advanced stages are unable to read, watch TV, drive, or use computers.
This video is not supported by your browser at this time.
There are two forms of AMD: 'dry' and 'wet'. Dry AMD accounts for the majority of cases, but wet AMD causes over 90% of blindness associated with the disease. In wet AMD, blood vessels underneath the retina begin to grow abnormally, which causes almost immediate central blindness. Because central vision accounts for almost all of our daytime visual acuity, wet AMD sufferers experience severe and profound day-to-day challenges.
Treatment options for wet AMD are currently limited to the end stages of the disease. Regular injections of antibodies must be made directly into the eye to mop up a problematic molecule termed 'VEGF'. However, the Trinity scientists found that IL-18 directly inhibits VEGF production, and that it can work as effectively as the current treatment when administered via a non-invasive intravenous injection in pre-clinical settings.
"Our findings have highlighted the power of industry-academic collaborations, the results of which should lead to clinical deployment of IL-18 as a treatment for AMD in the short term," added Research Assistant Professor in Genetics at Trinity, Matthew Campbell.
The research, published online this week in the high-profile international journal, Science Translational Medicine, was supported by Enterprise Ireland (EI), Science Foundation Ireland (SFI), the US-based charity Brightfocus Foundation, and major pharmaceutical company GlaxoSmithKline (GSK).
Vice President of Ophthalmology at GSK, Dr Pete Adamson, said: "A greater understanding of the molecular complexity of diseases such as AMD is critical to the development of new medicines."
Explore further: Impaired autophagy associated with age-related macular degeneration
More information: "IL-18 Attenuates Experimental Choroidal Nascularization as a Potential Therapy for Wet Age-Related Macular Degeneration," by S.L. Doyle et al. Science Translational Medicine, 2014.
Medical Xpress on facebook
Related Stories
Scientists report major breakthrough in age-related macular degeneration prevention
Apr 08, 2012
Scientists at Trinity College Dublin have discovered that a part of the immune system called the inflammasome is involved in regulating the development of one of the most common forms of blindness, called Age-Related Macular ...
Impaired autophagy associated with age-related macular degeneration
Aug 21, 2013
A new study published in the prestigious PLoS One journal changes our understanding of the pathogenesis of age-related macular degeneration (AMD). The researchers found that degenerative changes and loss of vision are ca ...
Age-related macular degeneration treatment works even with other eye problem
Nov 11, 2012
The primary treatment for wet macular degeneration, a chronic eye condition that causes vision loss, is effective even if patients have macular traction problems, a Mayo Clinic study shows. The findings will be presented ...
Team finds potential topical treatment for macular degeneration
Oct 09, 2013
Researchers from Tufts University School of Medicine and the Sackler School of Graduate Biomedical Sciences have identified a possible topical treatment for age-related macular degeneration (AMD) in a study of mice that shows ...
Nano innovation could mean eye injections are a thing of the past
Mar 05, 2014
Drugs used to treat blindness-causing disorders could be successfully administered by eye drops rather than unpleasant and expensive eye injections, according to new research led by UCL scientists that could be a breakthrough ...
Recommended for you
New non-surgical treatment for common, vexing eye condition
Mar 31, 2014
A new report reveals a potential breakthrough in the treatment of a common eye ailment known as pterygium (Surfer's eye) that impacts the vision, eye health, and cosmetic appearance of countless sufferers.
Rates of blindness and partial sight have plummeted in developed world
Mar 24, 2014
Rates of blindness and impaired eyesight have plummeted over the past 20 years in the developed world. But macular degeneration has replaced cataract as the leading cause of blindness in rich countries, reveals an analysis ...
Physical activity and occasional drinking found to be associated with decrease in vision impairment
Mar 19, 2014
A physically active lifestyle and occasional drinking is associated with a reduced risk of developing visual impairment, according to a study published online this month in Ophthalmology, the journal of the American Academ ...
Color vision tends to fade with age, study finds
Mar 18, 2014
(HealthDay)—Here's one more ability that seems to decline with age: color sense. A new study finds that many people lose their ability to clearly distinguish certain colors as they age, with losses typically ...
Drivers with hemianopia fail to detect pedestrians
Mar 14, 2014
A diagnosis of hemianopia, or blindness in one half of the visual field in both eyes as the result of strokes, tumors or trauma often means the end of driving.
Smartphones become 'eye-phones' with low-cost devices developed by Stanford
Mar 07, 2014
Researchers at the Stanford University School of Medicine have developed two inexpensive adapters that enable a smartphone to capture high-quality images of the front and back of the eye. The adapters make ...
User comments
© Medical Xpress 2011-2014, Science X network
0 comments:
Post a Comment